亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial

医学 内科学 彭布罗利珠单抗 肿瘤科 结直肠癌 生活质量(医疗保健) 癌症 DNA错配修复 打开标签 微卫星不稳定性 化疗 随机对照试验 生物 护理部 等位基因 基因 免疫疗法 微卫星 生物化学
作者
Thierry André,Mayur M. Amonkar,Josephine M. Norquist,K-K. Shiu,Tae Won Kim,Benny Vittrup Jensen,Lars Henrik Jensen,Cornelis J.A. Punt,Denis Smith,Rocio García‐Carbonero,Isabel Sevilla,Christelle De La Fouchardière,Fernando Rivera,Elena Élez,Luis A. Díaz,Takayuki Yoshino,Eric Van Cutsem,Ping Yang,Mohammed Z.H. Farooqui,Dung T. Le
出处
期刊:Lancet Oncology [Elsevier]
卷期号:22 (5): 665-677 被引量:140
标识
DOI:10.1016/s1470-2045(21)00064-4
摘要

In the KEYNOTE-177 study, pembrolizumab monotherapy provided statistically significant and clinically meaningful improvements in progression-free survival versus chemotherapy as first-line treatment in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer. To further support the efficacy and safety findings of the KEYNOTE-177 study, results of the health-related quality of life (HRQOL) analyses are reported here.KEYNOTE-177 is an open-label, randomised, phase 3 trial being done at 192 cancer centres in 23 countries, in patients aged 18 years and older with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer, with an Eastern Cooperative Oncology Group performance status of 0 or 1, and who had not received previous systemic therapy for metastatic disease. Eligible patients were randomly assigned (1:1) centrally by use of interactive voice response or integrated web response technology to receive pembrolizumab 200 mg intravenously every 3 weeks or investigator's choice chemotherapy (mFOLFOX6 [leucovorin, fluorouracil, and oxaliplatin] or FOLFIRI [leucovorin, fluorouracil, and irinotecan] intravenously every 2 weeks with or without intravenous bevacizumab or cetuximab). Patients and investigators were not masked to treatment assignment. The primary endpoints were progression-free survival (previously reported) and overall survival (data to be reported at the time of the final analysis). HRQOL outcomes were evaluated as prespecified exploratory endpoints. The analysis population comprised all randomly assigned patients who received at least one dose of study treatment and completed at least one HRQOL assessment. HRQOL outcomes were mean change from baseline to prespecified week 18 in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and EORTC Quality of Life Questionnaire-Colorectal 29 (EORTC QLQ-CR29) scale and item scores, and in the EuroQoL 5 Dimensions 3 Levels (EQ-5D-3L) visual analogue scale and health utility scores; the proportion of patients with improved, stable, or deteriorated scores from baseline to prespecified week 18 in EORTC QLQ-C30 scales and items; and time to deterioration in EORTC QLQ-C30 global health status/quality of life (GHS/QOL), physical functioning, social functioning, and fatigue scores and EORTC QLQ-CR29 urinary incontinence scores. The threshold for a small and clinically meaningful mean difference in EORTC QLQ-C30 score was 5-8 points. This study is registered with ClinicalTrials.gov, NCT02563002 and is ongoing; recruitment is closed.Between Feb 11, 2016, and Feb 19, 2018, 307 patients were enrolled and randomly assigned to receive pembrolizumab (n=153) or chemotherapy (n=154). The HRQOL analysis population comprised 294 patients (152 receiving pembrolizumab and 142 receiving chemotherapy). As of Feb 19, 2020, median time from randomisation to data cutoff was 32·4 months (IQR 27·7-37·8). Least squares mean (LSM) change from baseline to prespecified week 18 showed a clinically meaningful improvement in EORTC QLQ-C30 GHS/QOL scores with pembrolizumab versus chemotherapy (between-group LSM difference 8·96 [95% CI 4·24-13·69]; two-sided nominal p=0·0002). Median time to deterioration was longer with pembrolizumab versus chemotherapy for GHS/QOL (hazard ratio 0·61 [95% CI 0·38-0·98]; one-sided nominal p=0·019), physical functioning (0·50 [95% CI 0·32-0·81]; one-sided nominal p=0·0016), social functioning (0·53 [95% CI 0·32-0·87]; one-sided nominal p=0·0050), and fatigue scores (0·48 [95% CI 0·33-0·69]; one-sided nominal p<0·0001).Pembrolizumab monotherapy led to clinically meaningful improvements in HRQOL compared with chemotherapy in patients with previously untreated microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer. These data, along with the previously reported clinical benefits, support pembrolizumab as a first-line treatment option for this population.Merck Sharp & Dohme, a subsidiary of Merck & Co, Kenilworth, NJ, USA.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
qzliyulin完成签到,获得积分20
33秒前
Dr_an完成签到 ,获得积分10
1分钟前
1分钟前
大Doctor陈发布了新的文献求助10
1分钟前
1分钟前
子卿完成签到,获得积分0
1分钟前
狂野果汁发布了新的文献求助10
1分钟前
科研通AI2S应助Dr_an采纳,获得10
1分钟前
大Doctor陈完成签到,获得积分10
1分钟前
oscar完成签到,获得积分10
1分钟前
Chen完成签到 ,获得积分10
2分钟前
高大的咚咚关注了科研通微信公众号
3分钟前
3分钟前
Dr_an发布了新的文献求助10
3分钟前
3分钟前
咸鱼卷完成签到 ,获得积分10
3分钟前
3分钟前
3分钟前
3分钟前
Owen应助科研通管家采纳,获得10
3分钟前
深情安青应助科研通管家采纳,获得10
3分钟前
TAOTAO完成签到,获得积分20
3分钟前
TAOTAO发布了新的文献求助10
4分钟前
4分钟前
4分钟前
seven发布了新的文献求助10
4分钟前
wanjingwan完成签到 ,获得积分10
5分钟前
炸鸡叔完成签到 ,获得积分10
5分钟前
枫于林完成签到 ,获得积分10
5分钟前
6分钟前
刘海洋发布了新的文献求助30
6分钟前
李伟发布了新的文献求助10
6分钟前
星辰大海应助Narcissa采纳,获得30
6分钟前
5High_0完成签到 ,获得积分10
7分钟前
7分钟前
与山发布了新的文献求助10
7分钟前
7分钟前
刘海洋发布了新的文献求助10
7分钟前
Narcissa发布了新的文献求助30
7分钟前
科研通AI2S应助科研通管家采纳,获得10
7分钟前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Foreign Policy of the French Second Empire: A Bibliography 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3146728
求助须知:如何正确求助?哪些是违规求助? 2798015
关于积分的说明 7826552
捐赠科研通 2454530
什么是DOI,文献DOI怎么找? 1306360
科研通“疑难数据库(出版商)”最低求助积分说明 627704
版权声明 601522